SG
KTTA icon

StoneX Group’s Pasithea Therapeutics KTTA Stock Holding History

StoneX Group’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-600
Closed -$12.1K – 443
2022
Q2 		$12.1K Buy
+600
New +$12.8K ﹤0.01% 454

Other funds holding KTTA

KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OWP
Old Well Partners Charlotte, North Carolina $4.55M AUM 27.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

StoneX Group's KTTA Position: Q3 2022 in Review

StoneX Group sold out of Pasithea Therapeutics (KTTA) in Q3 2022, closing a stake of 600 shares — an estimated $12.1K sold.

StoneX Group first reported a position in KTTA in Q2 2022 and held it in 1 quarter. The position peaked at $12.1K in Q2 2022. 9 funds tracked by Wall St. Rank hold KTTA as of Q3 2022.

  • StoneX Group reported no remaining Pasithea Therapeutics position as of Q3 2022 after selling out during the quarter.
  • StoneX Group sold 600 Pasithea Therapeutics shares in Q3 2022, an estimated $12.1K.
  • StoneX Group first reported a position in Pasithea Therapeutics in Q2 2022 and held it in 1 quarter.
  • StoneX Group's Pasithea Therapeutics position peaked at $12.1K in Q2 2022.
  • 9 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q3 2022.

Based on StoneX Group's 13F filing for Q3 2022, filed 8 Nov 2022.